Image courtesy of Philips Healthcare November 20, 2012 — TeraRecon Inc. has received the North American New Product Innovation Award in Medical Imaging Informatics from the respected independent research firm Frost and Sullivan. This award represents the seventh time that TeraRecon Inc. has been recognized with a Best Practices award from Frost and Sullivan, and the third time since 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications and the North American Growth Leadership of the Year Award. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2012.pdf.The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American Medical Imaging Informatics market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon.To quote Frost and Sullivan: “In recognition of the role of product innovation and an entrepreneurial spirit in this continued success, Frost and Sullivan is proud to present TeraRecon with the 2012 North American New Product Innovation Award in Medical Imaging Informatics.” Regarding the value of healthy competition in the advanced visualization marketplace, Frost and Sullivan commented on mergers and acquisitions, observing that “the latest acquisition brought a major independent vendor under the control of a major imaging equipment manufacturer. Since then, the imaging equipment makers collectively have strengthened their grip over the advanced visualization market…” In this context, TeraRecon is the largest independent, vendor-neutral provider of advanced visualization, globally.Frost and Sullivan recognized the importance of combining a strong clinical value proposition with a viable and financially sound proposal in terms of department-wide and enterprise-wide information technology, and TeraRecon’s success in achieving this balance: “The cumulative impact of the solutions provided by TeraRecon has been highly regarded by IT departments and CIOs for its immediate and long-term ROI. It allows imaging providers seeking clinical excellence to also align their incentives with and get buy-in from their IT counterparts.”The award noted that “…the recently launched iNtuition Review, iNtuition Enterprise Medical Viewer (iEMV) and iNtuition Share product lines collectively incorporate a comprehensive range of elements necessitated by modern medical imaging enterprises to maintain peak operational efficiency and quality of care. These capabilities align perfectly with concerted industry demands for solutions that effectively lead to increased access to patient information and streamlined delivery of care.”It was observed that TeraRecon technology is embraced by a range of imaging professionals involved in clinical imaging as well as research: “A clear example of that vision is the company’s first-of-its-kind cloud-based advanced visualization service, which has garnered traction among certain types of imaging providers, as well as among contract research organizations (CRO) and other actors within the clinical trials field.”The importance of quantitative imaging and the company’s commitment to this field was also highlighted: “TeraRecon’s leadership in quantitative imaging offers providers the opportunity to enhance their clinical decision-support capabilities by being able to more efficiently document, store, and mine image-based analytics.”Building upon the value proposition of advanced imaging applications, Frost and Sullivan further highlighted the practical value of the iNtuition solution in the context of image sharing: “iNtuition SHARE provides yet another good example of value-added benefits leading to positive changes in ROI for providers. Its enterprise distribution and image-sharing capabilities connect medical imaging specialists with their referral base as well as their peers, patients and external facilities in a much more efficient way than the traditional CD-based model.”TeraRecon Chairman, president and CEO Robert Taylor, Ph.D., commented on the award, “We are truly honored to have received a seventh Frost and Sullivan award and the third within as many years, recognizing the company’s continuing achievements in the field of Medical Imaging Informatics. This independent research by Frost and Sullivan insightfully recognizes the important balance we have strived to achieve, between excellence in clinical advanced visualization tools, and enterprise access and interoperability, to ensure such tools are accessible, efficient, and effective in delivering excellence in care at an appropriate cost.”Taylor continued, “TeraRecon is fully committed to innovation and excellence, both technologically and clinically. We are defining new boundaries for advanced visualization and empowering physicians to communicate, share and cooperate with appropriate contextual tools for image review, every day. We embrace this challenge with the greatest enthusiasm and commitment.”For more information: www.frost.com, www.terarecon.com FacebookTwitterLinkedInPrint分享 Related Content News | Advanced Visualization | July 03, 2019 TeraRecon Unveils iNtuition AI Data Extractor Artificial Intelligence (AI) and advanced visualization company TeraRecon announced its new iNtuition AI Data Extractor… read more News | November 20, 2012 TeraRecon Receives 2012 New Product Innovation Award in Medical Imaging Informatics Technology | Virtual and Augmented Reality | June 04, 2019 Ann Arbor Startup Launches Augmented Reality MRI Simulator SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially… read more Feature | Advanced Visualization | July 02, 2019 | By Jeff Zagoudis Augmented Reality Versus 3-D Printing for Radiology Three-dimensional (3-D) printing and… read more Feature | Molecular Imaging | July 01, 2019 | By Sharvari Rale Transformations in Molecular Imaging Herald Entry to Novel Applications Diagnostic procedures have always been a cornerstone of early prognosis and patient triaging. read more Technology | Virtual and Augmented Reality | June 10, 2019 Medivis SurgicalAR Gets FDA Clearance Medivis announced that its augmented reality (AR) technology platform for surgical applications, SurgicalAR, has… read more News | Medical 3-D Printing | August 08, 2019 RSNA and ACR to Collaborate on Landmark Medical 3D Printing Registry The Radiological Society of North America (RSNA) and the American College of Radiology (ACR) will launch a new medical… read more Technology | Advanced Visualization | June 13, 2019 Materialise Receives FDA Clearance for Cardiovascular Planning Software Suite Three-dimensional (3-D) printing software and solutions company Materialise has received U.S. Food and Drug… read more Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor Innovations in Radiotherapy and Radiology at Henry Ford Hospital Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res read more Technology | Artificial Intelligence | June 20, 2019 TeraRecon Receives First-of-Kind FDA Determination for Northstar AI Results Explorer Advanced visualization and artificial intelligence (AI) technology provider TeraRecon has successfully completed a U.S… read more A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model. Photo courtesy of Nicole Wake, Ph.D. Technology | Neuro Imaging | August 07, 2019 Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release… read more Henry Ford Hospital’s ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.